Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in...
Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in reimbursement rates, upping its revenue projection on the company to $675M from $626M and its EPS estimates from $3.67 to $4.21.
From other sites
at Zacks.com (Mon, 3:59PM)
at Zacks.com (Mon, 8:57AM)
at 4-traders.com (Mon, 7:01AM)
at Nasdaq.com (Apr 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs